Ankara Yildirim Beyazıt University Initiates Clinical Trial Combining Extracorporeal Shock Wave Therapy and Blood Flow Restriction for Patients with Lateral Epicondylitis
Paradigm Shift in Chronic Tendinopathy Treatment and Unmet Medical Needs
Lateral epicondylitis, commonly known as tennis elbow, is a chronic condition characterized by degenerative changes and pain in the elbow tendon. Conventional treatments such as nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroid injections provide only temporary pain relief and are associated with high recurrence rates and potential side effects, highlighting the need for non-invasive therapies that promote tissue regeneration and functional recovery. The global lateral epicondylitis treatment market is projected to grow at an annual rate of approximately 4%, reaching USD 2.16 billion by 2032 from USD 1.6 billion in 2024. This significant market demand underscores the growing need for non-invasive, curative complex rehabilitation therapies.
Mechanism of Tissue Regeneration and Angiogenesis via Extracorporeal Shock Wave Therapy
The core of this clinical trial is radial extracorporeal shock wave therapy (Radial ESWT), a physical therapy that delivers high-energy acoustic waves to the affected area, inducing tendon cell proliferation. This technique stimulates vascular endothelial growth factor (VEGF) and nitric oxide (NO) synthesis, promoting microvascular formation, and induces the expression of transforming growth factor-beta 1 (TGFβ1) and insulin-like growth factor-1 (IGF-1), aiding tissue repair. While ESWT monotherapy has demonstrated efficacy in pain reduction and functional recovery, it has limitations in inducing muscle strength around the joints.
Synergistic Muscle Strengthening Effect of Blood Flow Restriction Therapy
To overcome these limitations, blood flow restriction (BFR) therapy has been introduced. This method involves applying a pressure cuff proximally to restrict arterial blood flow to 40–50% and block venous return. By creating a hypoxic environment within the muscle, BFR activates slow-twitch muscle fibers and stimulates protein synthesis, inducing muscle hypertrophy and strength enhancement even with low-intensity exercise. Previous studies have confirmed the effectiveness of BFR monotherapy in improving grip strength and upper limb function. Therefore, combining the tendon cell proliferation effect of extracorporeal shock wave therapy with the muscle hypertrophy promotion effect of BFR therapy can generate a powerful regenerative synergy.
Clinical Design and Evaluation Metrics of Medical Value
Led by researchers at Ankara Yildirim Beyazıt University, this clinical trial is a randomized controlled trial (RCT) involving 52 patients. Participants are divided into a combination therapy group and a monotherapy group, receiving weekly treatments for four weeks. Pain indices (VAS) and grip strength changes are measured using a Jamar hand dynamometer. The research team plans to track long-term muscle function recovery through isometric wrist flexion and extension strength measurements and the DASH questionnaire. The clinical trial commenced in April 2025, and patient recruitment is actively ongoing with the goal of completion by April 2027.
Innovation in Rehabilitation Medicine and Future Implications
If the combination of the two therapies demonstrates superior efficacy, it could trigger a significant shift in non-invasive musculoskeletal treatment protocols. In particular, companies such as Enovis (NYSE: ENOV), which develop extracorporeal shock wave therapy and BFR devices, could see expanded market share and increased sales. This approach could serve as an alternative to surgical or steroid injection treatments, reducing patients' economic burden and improving their quality of life.
This clinical trial holds significant medical value as it aims to establish a standard guideline for non-invasive complex rehabilitation in the lateral epicondylitis treatment market, which was valued at USD 1.6 billion in 2024. It is a randomized controlled trial (RCT) involving 52 patients, designed to validate a non-pharmacological alternative combining angiogenesis and muscle hypertrophy mechanisms, in contrast to conventional treatments with high recurrence rates such as NSAID use or corticosteroid injections. In the short term, the clinical data results, expected by April 2027, are anticipated to positively impact the sales of ESWT and BFR-related devices by orthopedic equipment companies such as Enovis (NYSE: ENOV). In the medium to long term, if this therapy is incorporated into standard rehabilitation protocols for degenerative diseases, it could accelerate insurance coverage for non-surgical treatments and drive demand for equipment in clinics and hospitals. Therefore, healthcare investors and industry professionals should pay close attention to the potential of this standard treatment, which minimizes drug side effects, to serve as a long-term growth driver for the musculoskeletal device market.
Source: ClinicalTrials.gov (api_ct)